Skip navigation
Please use this identifier to cite or link to this item: http://repositorio.unb.br/handle/10482/29016
Files in This Item:
File Description SizeFormat 
ARTIGO_InibidoresFosfodiesteraseTipo.pdf300,82 kBAdobe PDFView/Open
ARTIGO_PhosphodiesteraseTypeInhibitors.pdf254,84 kBAdobe PDFView/Open
Title: Inibidores da fosfodiesterase do tipo 5 e perda auditiva neurossensorial súbita
Other Titles: Phosphodiesterase type 5 Inhibitors and sudden sensorineural hearing loss
Authors: Barreto, Monique Antunes de Souza Chelminski
Bahmad Júnior, Fayez
Assunto:: Inibidores de fosfodiesterase
Surdez
Zumbido
Issue Date: Dec-2013
Publisher: Associação Brasileira de Otorrinolaringologia e Cirurgia Cervicofacial
Citation: BARRETO, Monique Antunes de Souza Chelminski; BAHMAD JÚNIOR, Fayez. Inibidores da fosfodiesterase do tipo 5 e perda auditiva neurossensorial súbita. Brazilian Journal of Otorhinolaryngology, São Paulo, v. 79, n. 6, p. 727-733, nov./dez. 2013. DOI: http://dx.doi.org/10.5935/1808-8694.20130133. Disponível em: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942013000600727&lng=pt&nr m=iso&tlng=pt. Acesso em: 03 ago. 2020. _________________________________________________________________________________________________________________________________________________________
BARRETO, Monique Antunes de Souza Chelminski; BAHMAD JÚNIOR, Fayez. Phosphodiesterase type 5 Inhibitors and sudden sensorineural hearing loss. Brazilian Journal of Otorhinolaryngology, São Paulo, v. 79, n. 6, p. 727-733, nov./dez. 2013. DOI: http://dx.doi.org/10.5935/1808-8694.20130133. Disponível em: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942013000600727&lng=pt&nr m=iso&tlng=pt. Acesso em: 03 ago. 2020.
Abstract: O uso de inibidores da fosfodiesterase do tipo 5 como sildenafil, vardenafil e tadalafil tem aumentado atualmente e alguns destes pacientes vêm apresentando perda auditiva neurossensorial súbita. OBJETIVO: Apresentar dois casos de pacientes que apresentaram surdez súbita em uso eventual do medicamento e revisar estudos sobre o uso de inibidores da fosfodiesterase do tipo 5 e surdez súbita. MÉTODO: Estudo analítico de dois casos e revisão sobre o tema no banco de dados da Pubmed/ MedLine e Bireme utilizando as palavras-chave inibidores da fosfodiesterase e surdez súbita e seus correlatos na língua inglesa. RESULTADOS: Os pacientes analisados são jovens, sem comorbidades, em uso de inibidores da fosfodiesterase do tipo 5 e após terapia combinada para o tratamento da surdez súbita, apenas um deles obteve melhora auditiva. Nove estudos científicos foram encontrados. Estudos pré-clínicos e clínicos, transversais e prospectivos foram revisados. CONCLUSÃO: O aumento da ocorrência na prática clínica e relatos científicos na literatura sugerem que o uso de inibidores da fosfodiesterase do tipo 5 seja encarado como fator de risco para surdez súbita. Novos estudos com amostras maiores e grupo controle são necessários para investigar esta associação.
Abstract: Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss. OBJECTIVE: To present two patients with sudden deafness developed after an occasional use of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and sudden hearing loss. METHOD: Analytical study of two cases and review of the subject matter in the Pubmed/Medline and Bireme databases using the keywords: phosphodiesterase type 5 inhibitors and sudden deafness and its correlates in the English language. RESULTS: The patients analyzed are young without additional disorders, using phosphodiesterase type 5 inhibitors, and after combination treatment for sudden hearing loss only one had hearing improvement. We found nine scientific studies and reviewed preclinical studies, clinical trials, prospective and cross-sectional investigations. CONCLUSION: Increased occurrence in clinical practice and scientific reports in the literature suggest that the phosphodiesterase type 5 inhibitors are considered a risk factor for sudden deafness. Further studies with larger samples and control groups are needed for better assessing this association.
Licença:: Brazilian Journal of Otorhinolaryngology - (CC BY-NC-ND) - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.. Fonte: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942013000600727&lng=pt&nrm=iso&tlng=pt. Acesso em: 03 ago. 2020.
DOI: https://dx.doi.org/10.5935/1808-8694.20130133
Appears in Collections:Artigos publicados em periódicos e afins

Show full item record " class="statisticsLink btn btn-primary" href="/jspui/handle/10482/29016/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.